KRAS mutation is a predictive biomarker for resistance to cetuximab (Erbitux) in metastatic colorectal cancer (mCRC). This study sought to determine if KRAS mutant CRC lines could be sensitized to cetuximab using dasatinib Sprycel), a potent, orally bioavailable inhibitor of several tyrosine kinases, including the Src family kinases (SFKs). We analyzed 16 CRC lines for: (1) KRAS mutation status, (2) dependence on mutant KRAS signaling and (3) expression level of epidermal growth factor receptor (EGFR) and SFKs. From these analyses, we selected three KRAS mutant (LS180, LoVo and HCT116) cell lines and two KRAS wild-type cell lines (SW48 and CaCo2). In vitro, using poly-D-lysine/laminin plates, KRAS mutant cell lines were resistant to cetuximab, whereas KRAS wild-type lines showed sensitivity to cetuximab. Treatment with cetuximab and dasatinib showed a greater antiproliferative effect on KRAS mutant lines when compared with either agent alone in vitro and in vivo. To investigate potential mechanisms for this antiproliferative response in the combinatorial therapy, we performed Human Phospho-Kinase Antibody Array analysis, measuring the relative phosphorylation levels of 39 intracellular proteins in untreated, cetuximab, dasatinib or the combinatorial treatment in the KRAS mutant lines LS180, LoVo and HCT116 cells. The results of this experiment showed a decrease in a broad spectrum of kinases centered on the b-catenin pathway, the mitogen-activated protein kinase (MAPK) pathway, AKT/mammalian target of rapamycin (mTOR) pathway and the family of signal transducers and activators of transcription (STATs) when compared with the untreated control or monotherapy treatments. Next, we analyzed tumor growth with cetuximab, dasatinib or their combination in vivo. KRAS mutant xenografts showed resistance to cetuximab therapy, whereas KRAS wild type demonstrated an antitumor response when treated with cetuximab. KRAS mutant tumors exhibited minimal response to dasatinib monotherapy. However, as in vitro, KRAS mutant lines exhibited a response to the combination of cetuximab and dasatinib. Combinatorial treatment of KRAS mutant xenografts resulted in decreased cell proliferation, as measured by Ki67, and higher rates of apoptosis, as measured by TUNEL (terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling). The data presented in this study indicate that dasatinib can sensitize KRAS mutant CRC tumors to cetuximab and may do so by altering the activity of several key signaling pathways. Furthermore, these results suggest that signaling via EGFR and SFKs may be necessary for cell proliferation and survival of KRAS mutant CRC tumors. These data strengthen the rationale for clinical trials combining cetuximab and dasatinib in the KRAS mutant CRC genetic setting.
Introduction
The epidermal growth factor receptor (EGFR) is a member of the HER family of receptor tyrosine kinases (RTKs), which consists of four members: EGFR (ErbB1/HER1), HER2/Neu (ErbB2), HER3 (ErbB3) and HER4 (ErbB4). Stimulation of the receptor through ligand binding activates the intrinsic receptor tyrosine kinase and promotes receptor homo-or heterodimerization with HER family members. EGFR activation leads to the downstream stimulation of several signaling cascades, including RAS/RAF/ERK/MAPK, phosphatidylinositol 3-kinase (PI3K/Akt) pathway and the phospholipase C-g/protein kinase C (PLCg/PKC) pathway. In addition, several other pathways are activated, including Src family kinases (SFKs) and the signal transducers and activators of transcription (STATs). Collectively, these pathways influence several cellular responses, including cell proliferation, survival, migration, angiogenesis and metastasis (reviewed in Biscardi et al., 1999b; Abram and Courtneidge, 2000; Schlessinger, 2000; Blume-Jensen and Hunter, 2001; Prenzel et al., 2001; Yarden and Sliwkowski, 2001; Marmor et al., 2004) . Aberrant expression or activity of the EGFR is linked to the etiology of several human epithelial cancers, including head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC), brain cancer and colorectal cancer (CRC). Therefore, the EGFR has emerged as one of the most promising molecular targets in oncology.
Although EGFR is activated through ligand binding and autophosphorylation of its cytoplasmic tail, it is well established that Src, or SFKs, are necessary for full activation of the EGFR (Biscardi et al., 1999a) . Src is the prototype member of a family of non-RTKs, including Src, Yes, Fyn, Lyn, Lck, Hck Fgr, Blk and Yrk. These membrane-associated non-RTKs are transducers of mitogenic signaling emanating from a number of RTKs, including EGFR, HER2, fibroblast growth factor receptor, platelet-derived growth factor, colonystimulating factor-1 receptor and hepatocyte growth receptor (Muthuswamy et al., 1994; Belsches et al., 1997; Mao et al., 1997; DeMali et al., 1999; Tice et al., 1999; Bowman et al., 2001) . Investigations into the molecular interactions between SFKs and EGFR have indicated that SFKs can physically associate with activated EGFR (Maa et al., 1995; Muthuswamy and Muller, 1995; Belsches-Jablonski et al., 2001) . This interaction results in a conformational change in the SFK and leads to autophosphorylation at Y419 and transient activity (Xu et al., 1999) . This interaction of SFKs with RTKs can result in enhanced or synergistic SFK activation, and has been demonstrated in several tumor types, most notably in HNSCC, NSCLC and CRC Zhang et al., 2007; Fu et al., 2008; Koppikar et al., 2008) .
Activation of SFKs occurs with high frequency during the development of CRC. An increase in SFK activity in CRC tumors when compared with normal adjacent mucosa has been reported (Bolen et al., 1987; Cartwright et al., 1989) . In addition, activation of SFKs was reported at an early stage of colorectal tumor development in polyps with high malignant potential but not in small benign polyps of the colon (Cartwright et al., 1990) . Furthermore, premalignant ulcerative colitis epithelium has been reported to have elevated SFK activity (Cartwright et al., 1994) , suggesting that the activity of SFKs may be a critical step in the development from non-malignant to malignant transformation in CRC. Talamonti et al. (1993) reported increased activity and expression of SFKs in progressive stages of human CRC, suggesting that CRC progression may be dependent on increased SFK protein level and subsequent activity. Similar studies by Termuhlen et al. (1993) , looking at CRC metastases to either the liver or the regional lymph nodes, exhibited increased SFK activity levels when compared with the primary tumor. Collectively, these studies suggest a putative link between increased SFK activity and metastatic potential in CRC. Irby et al. (1997) indicated that overexpression of wild-type c-Src in poorly metastatic human colon cancer cells enhances primary tumor growth but not the metastatic potential of these cancers. Additional studies by Irby et al. (1999) cited that activating mutations in Src, when compared with increased expression and activity of Src, in a subset of human CRC might have a role in the malignant progression of human CRC. Furthermore, it has been reported that increased SFK expression occurs in B80% of CRC specimens when compared with the normal adjacent colonic epithelium (Hurwitz et al., 2004) . Recent studies looking at 64 individual CRC cell lines found a striking diversity of SFK activity. The authors reported that all lines tested were dependent on SFK activity for growth (Emaduddin et al., 2008) . In addition to SFK activity and CRC progression, SFK activity has been reported as a marker of poor clinical prognosis (Aligayer et al., 2002) . Collectively, these investigations provide a wide body of evidence implicating Src and its family of kinases in CRC development and progression (for further review, see Summy and Gallick, 2003) . Regardless of the form of activation, activated SFKs lead to the phosphorylation of several targets, including the EGFR, STATs, PLCg, PKCs, focal adhesion kinase-1 (FAK), RAS, RAF and mucin 1 (Fabian et al., 1993; Li et al., 1994; Schaller et al., 1994 Schaller et al., , 2001a Yu et al., 1995; Denning et al., 1996; Bromberg et al., 1998; Blake et al., 1999; Biscardi et al., 2000; Kronfeld et al., 2000; Li and Kufe, 2001; Chiu et al., 2002; Joseloff et al., 2002; Kijima et al., 2002; Bivona et al., 2003; McLean et al., 2005) .
Targeting EGFR has been intensely pursued in the last decade and has resulted in the FDA (Food and Drug Administration) approval of five new molecular targeting agents since 2003 in four distinct solid tumors, including metastatic NSCLC, HNSCC, breast cancer and mCRC. One molecular strategy of EGFR inhibition has been the development of monoclonal antibodies (cetuximab and panitumumab) directed against the extracellular domain of the EGFR. This approach results in: (1) blockade of endogenous ligand binding to the receptor, (2) inhibition of dimerization with other HER family members and (3) receptor internalization and degradation. Cetuximab and panitumumab have been approved for the treatment of mCRC when used alone or in combination with irinotecan in patients with irinotecan-refractory mCRC (cetuximab) or as a single agent in patients who do not respond to all available chemotherapies (panitumumab).
Despite the approval of these promising biological therapeutics, many individuals do not respond to this class of drug. Intensive clinical trials have evaluated the outcomes of patients with mCRC in relation to their KRAS mutational status. The conclusions of this analysis demonstrated a strong correlation between mutated KRAS and a lack of response to cetuximab therapy, indicating that KRAS status serves as a predictive factor (Lievre et al., 2006; Benvenuti et al., 2007;  and for full review, Bardelli and Siena 2010) . On the basis of these clinical trials, the American Society of Clinical Oncology published guidelines that strongly support the use of anti-EGFR antibodies in mCRC patients with wild-type KRAS status (Allegra et al., 2009; Bardelli and Siena, 2010) . These guidelines leave very few therapeutic options for mCRC patients harboring a KRAS mutation.
In this report we investigated whether or not targeting both EGFR and SFKs, in the KRAS mutant CRC setting, would lead to antiproliferative effects on colon tumor growth. We found that dasatinib treatment could sensitize KRAS mutant, cetuximab-resistant cells to cetuximab therapy in vitro and in vivo. This combinatorial therapy led to altered signaling in: (1) components of the MAPK pathway, (2) the b-catenin pathway and (3) several members of the STAT family of transcription factors. Taken together, these results suggest that the EGFR and SFKs have a role in the KRAS mutant CRC setting and that dual targeting of the EGFR and SFKs with dasatinib and cetuximab may be a beneficial approach in this genetic subset of mCRC patients.
Results
Characterization and selection of KRAS mutant colorectal tumor lines We screened 16 CRC lines for the expression of EGFR and SFKs (Figure 1a ). Of these 16 lines, 14 expressed EGFR and all lines expressed SFKs. Relative EGFR and SFK expression was quantitated using ImageJ (NIH, Bethesda, MD, USA) and normalized to Co-lo320DM and SW620 for EGFR and SW48 for total SFK. Next, we screened each line for KRAS mutations at codons 12 and 13 and for BRAF mutations at codon 600 by pyrosequencing ( Figure 1b ). Of the 16 lines, 9 had a KRAS mutation. Four cell lines (LS123, LS180, SW480 and SW620) had a mutation at codon 12, whereas five lines (DLD1, HCT115, HCT116, LoVo and SW1417) had a mutation at codon 13. Of the 16 lines, 2 (HT29 and WiDr) demonstrated BRAF mutations. BRAF mutations were analyzed to ensure that selected lines were mutated for KRAS only. To further analyze these tumor cells, we performed in vivo tumor growth analysis to determine the ability of each CRC cell line to grow in vivo. For this analysis, 1.0 Â 10 6 cells were inoculated into the dorsal flank of athymic nude mice and allowed to grow for 4 weeks. The results of this study showed that 12 of 16 lines were able to form tumors in vivo (annotated with an asterisk in Figure 1a ). From these results we selected three lines, LS180, LoVo and HCT116, for further studies. To determine their dependence on KRAS, we performed proliferation assays using small interfering RNAs targeting KRAS ( Figure 1c ). Results from this study showed that each line had dependence on mutated KRAS. Significant reductions of KRAS protein levels were demonstrated by western blot analysis (Figure 1c , inset). In addition, 
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KRAS mutation Figure 1 Characterization of colorectal tumor lines. (a) Analysis of EGFR and SFK expression in colon cancer lines. CRC tumor lines were grown and whole cell lysates were obtained, fractionated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotted for the indicated proteins. a-Tubulin was used as a loading control. All 16 tumor lines were tested for in vivo tumor growth using mouse xenografts. Tumor lines that grew 4500 mm 3 in vivo are denoted by *. Densitometry measurements of EGFR and SFK relative to Colo320DM and SW620 (1.0) for EGFR and SW48 (1.0) for SFK are shown. (b) KRAS and BRAF mutational status was determined via pyrosequencing. (c) KRAS mutant lines LS180, LoVo and HCT116 are dependent on KRAS. KRAS mutant lines LS180, LoVo and HCT116 were treated with transfection reagent only (vehicle), scramble small interfering RNA (siRNA; 10 nM) or KRAS siRNA (10 nM). Proliferation was measured at 72 h after treatment using the proliferation assay as described in the experimental procedures and plotted as a percentage of growth relative to the untreated control cells. Data points are represented as mean±s.e.m. (n ¼ 4). *Po0.05. Inset denotes confirmation of KRAS knockdown.
Dasatinib in KRAS mutant CRC EF Dunn et al these lines were screened for other known dasatinib targets such as c-KIT and platelet-derived growth factor receptor (PDGFR). Western blot analysis did not detect expression of these proteins in the three KRAS mutant lines (data not shown). Collectively, this analysis of CRC lines led to the selection of three KRAS mutant, EGFR-and SFK-expressing lines (LS180, LoVo and HCT116), two KRAS wild-type lines expressing EGFR and SFKs (CaCo2 and SW48) and one non-EGFR expressing, KRAS wild-type control line (Colo320DM).
Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab in vitro
We performed a series of in vitro experiments using two KRAS wild-type (CaCo2 and SW48) and three KRAS mutant lines (LS180, LoVo and HCT116) to investigate the mechanisms of sensitization of KRAS mutant CRC lines to cetuximab using dasatinib. To determine if KRAS mutant lines were resistant to cetuximab therapy in vitro, we performed a series of proliferation assays using plastic plates, fibronectin, laminin, fibronectin/ laminin or poly-D-lysine/laminin (PDL/laminin)-coated plates. KRAS mutant CRC cell lines were sensitive to cetuximab on plastic and fibronectin plates (data not shown); however, when plated on PDL/laminin plates, KRAS mutant lines showed decreased response to cetuximab, whereas KRAS wild-type lines showed increased sensitivity to cetuximab (Figure 2a ). Therefore, we used PDL/laminin plates for all in vitro studies. Next, we examined if dasatinib could sensitize KRAS mutant CRC lines to cetuximab therapy. We performed proliferation assays on PDL/laminin plates using dimethyl sulfoxide (DMSO) control, 100 nM cetuximab, 50 nM dasatinib or the combination on LS180, LoVo and HCT116 cell lines. The results of these experiments indicated that: (1) KRAS mutant lines were resistant to cetuximab, (2) dasatinib induced mild growth inhibition on KRAS mutant lines and (3) the combination of the two drugs led to decreased proliferation ( Figure 2b ). Figure 2c shows the effects of cetuximab, dasatinib and their combination on their respective kinase targets in KRAS mutant CRC cell lines. These results suggest that signaling via the EGFR and SFKs may be necessary for cell proliferation and survival of KRAS mutant CRC tumors. These data strengthen the rationale for combining cetuximab and dasatinib in the KRAS mutant setting.
Treatment of KRAS mutant CRC lines with dasatinib plus cetuximab results in distinct alterations of phospho-kinase activity
The development of CRC is characterized by a number of events that lead the normal mucosa through a transformation to dysplastic lesions, adenoma, adenocarcinoma in situ and finally to invasive adenocarcinoma. This progression has been linked to the overexpression and ultimate overactivation of the EGFR, KRAS and SFK signaling pathways. Many other alterations in cell signaling pathways have been documented to lead to CRC (Fearon and Vogelstein, 1990) . Given the beneficial results seen by the combination of dasatinib and cetuximab in each of the three KRAS mutant lines (Figure 2b ), we investigated potential mechanistic underpinnings that may have resulted in this beneficial effect. Given the complexity and cross-talk of each of these pathways, we elected to perform Human Phospho-Kinase Array (ARY003; R&D Systems, Minneapolis, MN, USA) analysis on each KRAS mutant line (LS180, LoVo and HCT116) treated with vehicle, cetuximab (500 nM), dasatinib (50 nM) or their combination. This Human Phospho-Kinase array analyzed 39 individual proteins involved in cellular proliferation and survival. Each cell line was plated on PDL/laminin plates and allowed to adhere overnight. Vehicle, cetuximab, dasatinib or the combination were placed onto the cells and allowed to incubate for 24 h. Protein lysates were collected and Human Phospho-Kinase arrays were analyzed for each treatment group in all three cell lines. The results of this series of experimentations were quantitated by ImageJ for each line and are summarized in Figure 3 . Interestingly, the results of this study showed a very unique kinase signature for each cell line treated with cetuximab, dasatinib or the combination.
Phospho-array analysis of LS180 identified several pathways which were downregulated by the combination of dasatinib and cetuximab. These pathways included the AKT/mammalian target of rapamycin (mTOR)/p70 S6 kinase pathway (AKT and p70 S6 Kinase), mitogen-activated protein kinase/ribosomal s6 kinase (RSK1/2/3) and components of the b-catenin pathway (glycogen synthase kinase a/b (GSK a/b) and b-catenin). In addition to signaling pathways, several key transcription factors were downregulated, including STAT1, STAT3, STAT4, STAT5A/B, STAT6 and p53. Other signaling molecules that were downregulated in the combination group included endothelial nitric oxide synthase (eNOS) and p27. Figure 3a presents a histogram of the notable changes.
In LoVo, the members of the MAPK signaling pathway appeared to be downregulated with the combination of dasatinib and cetuximab including MAPK kinase (MEK 1/2) and mitogen and stressactivated protein kinase (MSK 1/2). With regard to transcription factor activity, the combination of dasatinib and cetuximab resulted in modulation of phosphorylation of several STAT family members, including STAT2, STAT3, STAT5A, STAT5B and STAT6. Other signaling molecules that were downregulated with the combination treatment included AMPKa1, HSP27 (heat shock 27 kDa protein 1) and most notably FAK. Figure 3b presents a histogram of the notable changes.
Phospho-array analysis of HCT116 identified similar pathways as in LS180. These pathways included the AKT/mTOR/p70 S6 kinase pathway (AKT and p70 S6 kinase), MAPK/RSK (RSK1/2/3) and components of the b-catenin pathway (GSK a/b and b-catenin). However, like LS180 and LoVo, the combination seemed to have effects on the STAT transcription factor family, including STAT1, STAT2, STAT4, STAT5A, STAT5B and STAT6. Other signaling molecules that were downregulated in the combination group included p27, paxillin and AMPKa1. Figure 3c presents a histogram of the notable changes.
Collectively, these results suggest that three independent KRAS mutant, cetuximab-resistant CRC tumor lines have several shared cell signaling pathways affected by the combination of cetuximab and dasatinib, with the most notable similarities in the MAPK pathway, AKT/ mTOR pathway, b-catenin pathway and the activation of the STAT family of transcription factors.
Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab in vivo Next, we performed a series of mouse xenograft studies to confirm that KRAS wild-type CRC lines are sensitive to cetuximab therapy in vivo. For controls, we utilized a KRAS wild-type, non-EGFR-expressing CRC line, Colo320DM (Figure 4a ) and as a positive control we utilized a known EGFR-expressing, cetuximab-sensitive NSCLC line, H226 (Figure 4b ). Two KRAS wild-type lines, SW48 and CaCo2, were tested for response to cetuximab in vivo (Figures 4c and d) . Mice were injected bilaterally with 2 Â 10 6 tumor cells, grown to 50 mm 3 and randomized to treatment groups. In all studies, each group (IgG and cetuximab) had 10 mice (20 tumors) per arm. Mice were randomized and treated twice weekly with 0.3 mg of cetuximab or 0.3 mg of immunoglobulin G (IgG) for the indicated times. The data in Figures 4a and b indicate that the EGFR-negative line showed no off-target effects of cetuximab, whereas H226 showed a similar response to cetuximab as previously reported (Wheeler et al., 2008) . Both KRAS wild-type lines, SW48 and CaCo2, showed a statistically significant response to cetuximab treatment. In Figure 5 , we performed a series of experiments using three KRAS mutant CRC lines (LS180, LoVo and HCT116) to test cetuximab and dasatinib as single agents, given sequentially, or in combination. For the single-agent experiments (Figures 5a-c, cetuximab; upper left panels, dasatinib; upper right panels), mice were injected bilaterally with 2 Â 10 6 tumor cells, grown to 50 mm 3 and randomized to treatment groups. For LS180, 40 mice were analyzed: 10 in the IgG control arm (20 tumors), 10 in the cetuximab arm (20 tumors), 10 in the vehicle arm (20 tumors) and 10 in the dasatinib arm (20 tumors). For LoVo, 42 mice were analyzed: 10 in the IgG control arm (20 tumors), 11 in the cetuximab arm (22 tumors), 10 in the vehicle arm (20 tumors) and 11 in the dasatinib arm (22 tumors). For HCT116, 40 mice were analyzed: 10 in the IgG control arm (20 tumors), 10 in the cetuximab arm (20 tumors), 10 in the vehicle arm (20 tumors) and 10 in the dasatinib arm (20 tumors). Each line was treated with cetuximab (0.3 mg twice weekly) or dasatinib (70 mg/kg daily) for the indicated times. The results confirmed the clinical finding that these tested KRAS mutant lines were resistant to cetuximab. Dasatinib monotherapy in HCT116 and LoVo showed minimal tumor growth delay and was not shown to be statistically significant, whereas treatment of LS180 with dasatinib appeared to have a slight antiproliferative effect.
Next, we performed both sequential (cetuximab followed by dasatinib) and combinatorial treatment regimens. For the sequential experiments (Figures 5a-c , lower left panels), mice were injected bilaterally with 2 Â 10 6 tumor cells, grown to 50 mm 3 and randomized to treatment groups. For LS180, 24 mice were analyzed: 10 in the IgG/vehicle control arm (20 tumors) and 14 in the cetuximab/dasatinib arm (28 tumors). For LoVo, 22 mice were analyzed: 10 in the IgG/vehicle control arm (20 tumors) and 12 in the cetuximab/dasatinib arm (24 tumors). For HCT116, 20 mice were analyzed: 10 in the IgG/vehicle control arm (20 tumors) and 10 in the cetuximab/dasatinib arm (20 tumors). Mice were given cetuximab or IgG (0.3 mg) twice weekly by intraperitoneal injection until tumors demonstrated a resistant phenotype-defined as growth without deviation from the IgG controls. At this time, cetuximab and IgG were ceased and dasatinib or vehicle was started the next day for 5 days a week by oral gavage (70 mg/kg). Treatment with dasatinib or vehicle was continued for the specified times. The results of these experiments indicated that sequential treatment could lead to an antitumor growth effect (Figures 5a-c, lower left panels) . The most pronounced effect was seen in the LS180 and LoVo sequential experiments.
In the combinatorial experiments (Figures 5a-c , lower right panels), mice were injected bilaterally with 2 Â 10 6 tumor cells, grown to 50 mm 3 and randomized to treatment groups. For LS180, LoVo and HCT116, 40 mice were analyzed: 20 in the IgG/vehicle control arm (40 tumors) and 20 in the cetuximab/dasatinib arm (40 tumors). Mice were treated with either the combination of IgG and vehicle or cetuximab (0.3 mg, twice weekly) and dasatinib (70 mg/kg, 5 times weekly) for the indicated times. These experiments demonstrated statistically significant tumor growth inhibition in the combinatorial treatment regimen compared with vehicle controls that was distinguishable after the first treatment in LS180 and LoVo cell lines (Pp0.001). HCT116 demonstrated a statistically significant response at the beginning (Pp0.05) and by the end of treatment Dasatinib in KRAS mutant CRC EF Dunn et al (Pp0.001), although the response was modest compared with the other two KRAS mutated cell lines. Collectively, this series of mice xenograft experiments suggests that sequential or combinatorial treatment regimens of cetuximab and dasatinib may be effective in KRAS mutant CRC tumors. In addition, the combination of cetuximab and dasatinib appears to be more efficacious than the sequential experiments.
Combinatorial dasatinib and cetuximab treatment decreases proliferation and enhances apoptosis
To determine the impact of the combination of dasatinib plus cetuximab, we examined rates of cell proliferation and apoptosis in tumor samples from each line. Cell proliferation was analyzed by immunohistochemistry (IHC) for Ki67. Tumors were collected 3 h after the last dasatinib or vehicle treatment and 24 h after the last cetuximab or IgG treatment (Figure 6a ). In each respective line, Ki67 expression was decreased in the combination treatment arms ( þ ) compared with vehicle controls (À) (Figure 6a , Ki67 panels). To further analyze the effects of cetuximab and dasatinib on tumor growth, terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay was performed on tumor samples taken at the same time point. Results from this experiment demonstrated increased apoptosis in the combination treatment arms ( þ ) when compared with vehicle controls (À) (Figure 6a , TUNEL assay panels). Quantification of the IHC staining for Ki67 and TUNEL is shown in Figure 6b Figure 5 Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab. For the following series of experiments, all mice were randomized to treatment or control groups and treated with the following doses: cetuximab or IgG-0.3 mg/kg intraperitoneally twice per week; dasatinib-70 mg/kg by oral gavage 5 days a week. The same doses were used for sequential and combinatorial experiments. *(Pp0.001). (a-c, upper left panel) Cetuximab response was tested by inoculating mice with a KRAS mutant line (LS180, LoVo and HCT116, respectively) and randomizing to cetuximab or IgG. LS180 and LoVo mice received 3 weeks of treatment. HCT116 mice received 2.5 weeks of treatment. (a-c, upper right panel) Dasatinib response was tested by inoculating mice with a KRAS mutant line and randomizing to dasatinib or vehicle treatment. LS180 mice received 2.5 weeks of treatment. LoVo mice received 3 weeks of treatment. HCT116 mice received 4.5 weeks of treatment. (a-c, lower left panel) Sequential treatment response of cetuximab and then dasatinib was tested by inoculating mice with a KRAS mutant line and randomizing to cetuximab followed by dasatinib or IgG followed by vehicle. Cetuximab was ceased and dasatinib was started the next day once tumors displayed resistance. LS180 mice received 1 week of cetuximab/IgG and 2.5 weeks of dasatinib/vehicle. LoVo mice received 3 weeks of cetuximab/IgG and 2.5 weeks of dasatinib/vehicle. HCT116 mice received 2 weeks of cetuximab/IgG and 2.5 weeks of dasatinib/ vehicle. (a-c, lower right panel) Concomitant treatment response of cetuximab and dasatinib was tested by inoculating mice with a KRAS mutant line and randomizing to cetuximab plus dasatinib or IgG plus vehicle. LS180 mice received 2.5 weeks of concomitant treatment. LoVo mice received 3.5 weeks of concomitant treatment. HCT116 mice received 4 weeks of concomitant treatment. and control groups (66 and 68% decrease in proliferation, respectively). LS180 demonstrated a decrease in proliferation of 27%. All lines demonstrated a statistically significant increase in the percentage of apoptosis compared with vehicle controls based on TUNEL assays. LS180 demonstrated a 97% increase in apoptosis, LoVo demonstrated a 93% increase in apoptosis and HCT116 demonstrated a 71% increase in apoptosis. Collectively, this series of experiments suggests that the combination of cetuximab and dasatinib may lead to decreased tumor growth by increasing cell death (apoptosis) and decreasing cell proliferation (Ki67) in KRAS mutant CRC lines.
Discussion
Colon cancer continues to be the second most common cancer-related death in the United States (Jemal et al., 2008) . The etiology of mCRC is a complex series of genetic events that are characterized by several alterations, including p53, EGFR and SFK expression and mutations in KRAS (Fearon and Vogelstein, 1990; Summy and Gallick, 2003) . The EGFR protein is expressed in B85% of mCRC as measured by the specific binding of 125 I-EGFR to tumor plasma membrane preparations, western blotting and IHC (Normanno et al., 2003) . In addition, it is estimated that (Normanno et al., 2009; Bardelli and Siena, 2010) . Furthermore, it has been demonstrated in several clinical trials that patients with mCRC and a KRAS mutation do not respond to cetuximab therapy (Lievre et al., 2006; Benvenuti et al., 2007; Di Fiore et al., 2007; Khambata-Ford et al., 2007; Cappuzzo et al., 2008; De Roock et al., 2008; Karapetis et al., 2008) . These trial results leave a large population of patients with mCRC who cannot benefit from cetuximab therapy. The data presented in this study indicate that dasatinib can sensitize cetuximab-resistant, KRAS mutant CRC tumors to cetuximab. Furthermore, this combinatorial treatment was marked by downregulation of components of the MAPK, AKT/mTOR, b-catenin and STAT pathways.
30-40% of patients with CRC have a KRAS mutation
We screened 16 CRC lines for EGFR and SFK expression, KRAS or BRAF mutations and dependency on KRAS signaling (Figure 1 ). Next, we determined if these model systems mimic clinical findings in that KRAS mutant CRC lines would be resistant to cetuximab therapy. To test this hypothesis, we treated all KRAS mutant lines in vitro and challenged them with increasing concentrations of cetuximab (data not shown). The results of this indicated that KRAS mutant CRC lines showed a robust response to cetuximab on plastic plates and did not mimic what is seen in vivo and the clinic. Therefore, we performed a series of cell culture experiments using plastic plates, fibronectin, laminin, fibronectin/laminin or PDL/laminin-coated plates. These experiments indicated that PDL/laminin plates could most closely mimic clinical findings showing that KRAS mutant CRC lines were resistant to cetuximab (Figure 2a ). This finding suggests that the interaction between the extracellular matrix in vitro, and most likely in vivo, has a critical role in KRAS mutant CRC response to EGFR targeting agents. Viloria-Petit et al. (2001) reported that cetuximab-resistant lines, established in vivo, were sensitive to cetuximab in vitro (with plastic plates) after establishment of cell lines taken from mouse xenografts. Collectively, these findings underscore the importance of the experimental approach to study therapeutics targeting KRAS mutant CRC lines, and indicate that factors in the cell's environment are critical in the treatment of KRAS mutant CRC.
In Figures 2b and c, three KRAS mutant lines were tested for their response to cetuximab, dasatinib or the combination. Each line was resistant to cetuximab and semiresponsive to dasatinib. However, the combination of the two molecular targeting agents led to decreased proliferative potential when compared with either agent alone (Figure 2b ). We verified that cetuximab and dasatinib could reduce the activity of their respective targets (Figure 2c ). Although EGFR couples growth factor signaling to the RAS/RAF/MEK/ERK pathway, and mutations in KRAS uncouple this pathway from the receptor, the EGFR still has a role in the activation of other key pathways such as the PI3K/AKT pathway, STATs pathway and the PLCg/PKC pathways (Marmor et al., 2004) . These pathways may still be activated by EGFR, even in the KRAS mutant setting. To determine the effects of co-inhibition of SFKs and EGFR, we used phospho-array analysis on the three KRAS mutant CRC lines treated with vehicle, dasatinib, cetuximab or the combination. The results of these experiments revealed common pathways inhibited by the combination of these two agents in mutant KRAS CRC lines. First, in LS180 and HCT116, the b-catenin pathway appeared to be downregulated (Figures 3a and c) . This was evident by the decrease in phosphorylation of GSK3a and GSK3b. Decreased activity in this enzyme results in decreased b-catenin phosphorylation (also noted in the phospho-array), thus allowing it to translocate to the nucleus, where it binds the Lef/Tcf transcription factors and activates target genes involved in cancer progression. Second, in LS180 and HCT116, downregulation of the AKT/mTOR/p70S6 kinase pathway was noted. In both lines, activating phosphorylation events on AKT were decreased. AKT, through a series of complex signal transduction cascades, leads to the activation of the mTOR1 complex (Engelman, 2009 ). This serine-threonine kinase then phosphorylates p70 S6 kinase that leads to the increased translation of mRNAs that encode proteins for cell cycle regulators (MYC and cyclin D1) as well as ribosomal proteins and elongation factors involved in translation (reviewed in Rini, 2008) . Finally, in all three lines tested, the combination of dasatinib and cetuximab resulted in the downregulation of two pathways involved in tumor proliferation: (1) members of the STAT family and (2) members of the MAPK signaling cascade. The STAT family comprises seven members: STAT1-4, STAT5A, STAT5B and STAT6. Binding of growth factors or cytokines to their receptors results in intrinsic kinase activity or recruitment of receptor-associated kinases (Janus kinase and SFKs). These phosphorylated receptors in turn phosphorylate STATs on key residues, leading to their dimerization and translocation to the nucleus, where they regulate genes involved in cell proliferation, apoptosis, angiogenesis and tumor growth. In terms of the MAPK signaling pathway, the combination of dasatinib and cetuximab impacted proteins within this cascade, although at different levels of the pathway. At the terminal end of the classical RAS/RAF/MEK/ERK cascade sit two proteins: the 90 kDa RSK1 and MSK1/2. RSKs are phosphorylated at the end of the classical cascade where ERK phosphorylates RSK1 in the kinase activation loop (Richards et al., 1999) . Activation of RSK1 can lead to the phosphorylation of the proapoptotic protein BAD that, when phosphorylated, abrogates proapoptotic function of BAD (Shimamura et al., 2000) . In addition, RSK1 can phosphorylate IkBa, the inhibitor of nuclear factor-kb, inducing its degradation and allowing its translocation and function in the nucleus (Ghoda et al., 1997) . Decreased RSK1 phosphorylation was noted in LS180 and HCT116. MSK1/2 are believed to have a pivotal role in the activation of the CREB transcription factor by phosphorylation of serine 133 (Wiggin et al., 2002) . This molecule along with MEK1/2 was downregulated in LoVo. Collectively, these data suggest that therapeutic treatment with dasatinib and cetuximab results in the downregulation of several critical pathways involved in the progression of cancer.
Both in vitro and in vivo (Figures 2b and 5c ), the HCT116 data demonstrate a statistically significant response to the combination of cetuximab and dasatinib, but not as robust when compared with LS180 or LoVo data. This may be explained by the reported PI3K mutation in HCT116 (Jhawer et al., 2008; Wee et al., 2009) , which would lead to enhanced signaling through the AKT pathway, independent of cetuximab treatment. However, phospho-array analysis (Figure 3c ) showed decreased AKT activity when compared with either agent alone. This suggests that other, yet to be identified mechanisms exist for the decreased response to the combination in the HCT116 cell line.
Dasatinib is an orally bioavailable and promising therapeutic agent for the treatment of several human malignancies, including chronic myelogenous leukemia, NSCLC, small cell lung cancer, advanced breast cancer (including triple negative), pancreatic cancer, prostate cancer and HNSCC (reviewed in Kim et al., 2009) . Dasatinib was discovered through the synthesis and testing of a series of thiazole-based compounds with activity against SRC and ABL (v-abl Abelson murin leukemia viral oncogene homolog 1) kinases to target imatinib-resistant breakpoint cluster region (BCR)-ABL mutants (Kantarjian et al., 2006) . Dasatinib, although relatively specific for ABL, BCR-ABL and the SFKs, possesses a broad spectrum of inhibition of kinases, including c-KIT, PDGFR, EphA receptors and several others (Hantschel et al., 2008) . Nonspecific effects must always be considered when developing a mechanism but, regardless, the effect of cetuximab and dasatinib on antitumor growth is evident. The broad spectrum of kinase inhibition of dasatinib may, in part, be linked to its clinical success, as well as in combination with cetuximab in the KRAS mutant CRC setting. The combination of cetuximab and dasatinib has shown to be effective in overcoming acquired resistance to cetuximab in NSCLC (Li et al., 2009; Wheeler et al., 2009 ). In addition, clinical trials looking at this combination are currently in recruitment in HNSCC, mCRC and other solid tumors (http://clinicaltrials.gov).
KRAS is clearly a marker of resistance to cetuximab in monotherapy for CRC, and patient screening is still essential. However, our results suggest that KRAS mutant CRC lines are dependent on both signals from the EGFR and SFKs. Thus, the relationship between EGFR and SFK signaling in the presence of KRAS mutations will be an area of intense investigation. The concomitant treatment of dasatinib and cetuximab may be a viable option for KRAS mutant CRC patients without PI3K, or further downstream mutations. In addition, future directions may include investigations of this combination in the KRAS wild-type setting.
In summary, this study combines two FDA-approved agents, dasatinib and cetuximab, in the KRAS mutant CRC setting. From the data provided it appears that dasatinib can sensitize KRAS mutant tumors to cetuximab. This work may provide rationale for further investigative clinical trials using dasatinib plus cetuximab in patients with KRAS mutant, cetuximabresistant mCRC.
Materials and methods

Compounds
Cetuximab (C225, Erbitux) was purchased from the University of Wisconsin Pharmacy. Dasatinib (BMS-354825, Sprycel) was generously provided by Bristol-Myers Squibb (New York, NY, USA) .
Cell culture and transfection
The human CRC cell lines CaCo2, Colo320DM, DLD1, HCT15, HCT116, HT29, LoVo, LS123, LS180, SK-CO-1, SW48, SW480, SW620, SW948, SW1417 and WiDr were purchased from American Type Culture Collection (Manassas, VA, USA). All cell lines were maintained in their respective media with 10% fetal bovine serum with 1% penicillin and streptomycin, except for CaCo2, which was maintained in 20% fetal bovine serum and 1% penicillin and streptomycin. Colo320DM, DLD1 and HCT15 were maintained in RPMI-1640; HCT116 and HT29 were maintained in McCoy's media; LoVo was maintained in F12 media; CaCo2, LS123, LS180, SK-CO-1 and WiDr were maintained in Eagle's minimum essential medium; SW48, SW480, SW620, SW948 and SW1417 were maintained in L15 media (Life Technologies, Inc., Gaithersburg, MD, USA). LS180, LoVo and HCT116 cells were seeded in 6-wells or 96-well poly-D-lysine/laminin plates (BD Biosciences, San Jose, CA, USA) and transiently transfected with small interfering RNAs (siKRAS; Dharmacon, Lafayette, CO, USA) using Lipofectamine RNAiMAX according to the manufacture's instructions (Invitrogen, Carlsbad, CA, USA). The non-targeting small interfering RNA pool was obtained from Dharmacon. Cells were then lysed for analysis of protein knockdown by western blot or use in cell proliferation assays 72 h after small interfering RNA transfection.
Cell proliferation assay
Exponentially grown cells were seeded in 96-well poly-D-lysine/ laminin plates (BD Biosciences). Following 72 h of treatment, 10 ml of tetrazolium salt from cell counting kit (Dojindo Molecular Technologies, Rockville, MD, USA) was added to each well. After 1-4 h, the percentage of cell growth was calculated by comparison of the A 450 reading from treated versus control wells.
Pyrosequencing
Genomic DNA was isolated from cell lines using a standard proteinase K-phenol-chloroform extraction method. For PCR amplification of the relevant fragments, we used PyroMark KRAS and BRAF kits (Qiagen, Valencia, CA, USA) according to the manufacturer's protocols. The resulting PCR products were electrophoresed in 1.5% agarose gel to confirm successful amplification, and 40 ml of each sample was sequenced using a Pyrosequensing PSQ96HS System (Biotage, Uppsala, Sweden) according to the manufacturer's protocol.
Immunoblotting analysis
Whole cell protein lysate was obtained with lysis buffer (50 mM HEPES, pH 7.4, 150 mM NaCl, 0.1% Tween-20, 10% glycerol, 2.5 mM EGTA, 1 mM EDTA, 1 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride and 10 mg/ml of leupeptin and aprotinin), sonicated, fractionated and quantified. Cellular fractionation was performed as described previously (Wheeler et al., 2008) . Protein was quantitated using the Bradford method (Bio-Rad Laboratories, Hercules, CA, USA). Western blotting was performed as described previously (Wheeler et al., 2008) . Briefly, equal amounts of protein were fractionated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Thereafter, proteins were transferred to polyvinylidene fluoride membrane (Millipore, Billerica, MA, USA) and analyzed by incubation with the appropriate primary antibody. Proteins were detected via incubation with horseradish peroxidaseconjugated secondary antibodies and enhanced chemiluminescence detection system (GE Healthcare, Piscataway, NJ, USA). The antibodies used in this study, EGFR, horseradish peroxidase-conjugated goat-anti-rabbit IgG and goat-antimouse IgG, were purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). pEGFR 1173, SFK, pSFK and b-actin were obtained from Cell Signaling Technology (Beverly, MA, USA). Ki67 antibody was purchased from AbCam (Cambridge, MA, USA) and a-tubulin was obtained from Calbiochem (San Diego, CA, USA). ImageJ was used to evaluate densitometry of EGFR and SFK western blots.
Phospho-kinase array LS180, LoVo and HCT116 cell lines were analyzed in the panel of phosphorylation profiles of kinases after treatment with cetuximab, dasatinib and a combination of these compounds (Human Phospho-Kinase Array, ARY003; R&D Systems). This array specifically screens for relative levels of phosphorylation of 39 individual proteins involved in cellular proliferation and survival. After treatment with cetuximab (500 nM), dasatinib (50 nM) and their combination, cell lysates were incubated with the membrane. Thereafter, a cocktail of biotinylated detection antibodies, streptavidin-horseradish peroxidase and chemiluminescent detection reagents were used to detect the phosphorylated protein. The relative expression of specific photophorylated protein was determined following quantification of scanned images by ImageJ compared with cetuximab, dasatinib, their combination and vehicle.
Mouse xenograft model
Athymic nude mice (4-6-week-old males) were obtained from the Harlan Laboratories (Indianapolis, IN, USA). All animal procedures and maintenance were conducted in accordance with the institutional guidelines of the University of Wisconsin. Mice were randomized into treatment or control groups. Mice were injected bilaterally in the dorsal flank of the mouse at respective day 0 (2 Â 10 6 cells). Once tumors reached 50 mm 3 , mice were started on their respective treatments (cetuximab, IgG, dasatinib, vehicle, the combination of cetuximab and dasatinib, or the combination of IgG and vehicle). Cetuximab dose for all experiments was 0.3 mg intraperitoneally twice weekly. The dose of dasatinib for all experiments was 70 mg/kg and 5 days a week by oral gavage. Tumor volume measurements were evaluated by digital calipers and calculated by the formula (p)/6 Â (large diameter) Â (small diameter) 2 .
Mouse tumor collection and protein isolation
Mice were sedated using isofluorane mixed with oxygen until unconscious. Mice were euthanized by cervical dislocation and tumors were promptly collected, washed in phosphatebuffered saline, and frozen on dry ice or fixed in 10% formalin. Tumors were crushed using a mortar and pestle until the tumor was the consistency of a powder. Whole cell protein lysate was obtained with lysis buffer (50 mM HEPES, pH 7.4, 150 mM NaCl, 0.1% Tween-20, 10% glycerol, 2.5 mM EGTA, 1 mM EDTA, 1 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride and 10 mg/ml of leupeptin and aprotinin), sonicated and quantified. Cellular fractionation and protein quantitation were performed as stated above.
Ki67 and TUNEL assays
The ApopTag Plus Peroxidase in situ apoptosis detection kit was purchased from Millipore. Samples were prepared according to the manufacturer's recommended protocol with the modification of antigen retrieval instead of proteinase K. Antigen retrieval was performed in citrate buffer (pH ¼ 6.0) with 0.05% Tween-20. For IHC, tumor samples were fixed in 10% formalin for 24 h, paraffin embedded and serially cut onto slides. Samples were deparaffinized and antigen retrieval was performed in citrate buffer (pH ¼ 6.0) with 0.05% Tween-20. Samples were then incubated with Ki67 primary antibody (AbCam). Samples were washed and incubated in secondary antibody for 1 h followed by incubation with Vectastain Elite ABC kit (Vector Laboratories, Burlingame, CA, USA). 3,3-diaminobenzidine staining was done using Ultravision Plus Detection System (Lab Vision Corporation, Fremont, CA, USA). Images were captured using Biospot Advanced software (Diagnostic Instruments Inc., Sterling Heights, MI, USA). ImageJ was used to obtain total number of cells (via thresholding that was maintained across all samples). Color deconvolution was used to identify the positive staining and was thresholded across all image samples. All images for treatment (cetuximab plus dasatinib) and control (IgG plus vehicle) were averaged and s.e.m. was calculated. Ki67 samples were normalized to the vehicle images and TUNEL samples were normalized to the treatment (cetuximab plus dasatinib) images.
Statistical analysis
Student's t-test was used to determine the significance of the cell proliferation or tumor growth volumes between treatment and control groups for each in vitro and in vivo experiment, respectively. Statistical analysis to compare treatment and control groups in positive IHC staining was also done using t-test.
Abbreviations ABL, v-abl Abelson murin leukemia viral oncogene homolog 1; BCR, breakpoint cluster region; CRC, colorectal cancer; EGFR, epidermal growth factor receptor; eNOS, endothelial nitric oxide synthase; FAK, focal adhesion kinase-1; FDA, Food and Drug Administration; GSK a/b, glycogen synthase kinase a/b; HNSCC, head and neck squamous cell carcinoma; IgG, immunoglobulin G; IHC, immunohistochemistry; MAPK, mitogen-activated protein kinase; mCRC, metastatic colorectal cancer; MEK, MAPK kinase; MSK, mitogen and stressactivated protein kinase; mTOR, mammalian target of rapamycin; NSCLC, non-small cell lung cancer; PDL, poly-Dlysine; PDGFR, platelet-derived growth factor receptor; PI3K, phosphatidylinositol 3-kinase; PKC, protein kinase C; PLCg, phospholipase C-g; RSK, ribosomal s6 kinase; RTK, receptor tyrosine kinase; SFK, Src-family kinase; STAT, signal transducer and activator of transcription; TUNEL, terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling.
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